Health Score

0 Excellent

Metadata coverage

Abstract

ORCID

References

License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder

Award / grant

Affiliation & institutional identifiers

Affiliation

ROR ID

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

Attach ORCID iDs across 214 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact214 DOIs

Deposit reference lists for 16 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact16 DOIs

DOIs for this ISSN

Showing the top 5 of 793 DOIs, ordered by correction priority.

#	Title	Missing	Priority	Citations
1	Structure, Function, and Therapeutic Use of IgM Antibodies (10.3390/antib9040053)	ORCID	59.32	235
2	IgA: Structure, Function, and Developability (10.3390/antib8040057)	ORCID	59.23	233
3	David vs. Goliath: The Structure, Function, and Clinical Pro… (10.3390/antib8020028)	ORCID	58.51	218
4	Developments and Challenges for mAb-Based Therapeutics (10.3390/antib2030452)	ORCID	53.88	142
5	Antibody Aggregation: Insights from Sequence and Structure (10.3390/antib5030019)	ORCID	53.58	138
6	In Vivo Applications of Single Chain Fv (Variable Domain) (s… (10.3390/antib2020193)	ORCID	51.52	114
7	Bispecific T-Cell Redirection versus Chimeric Antigen Recept… (10.3390/antib8030041)	ORCID	51.42	113
8	Factors Affecting the Pharmacology of Antibody–Drug Conjugat… (10.3390/antib7010010)	ORCID	50.63	105
9	Introduction to Antibody-Drug Conjugates (10.3390/antib10040042)	ORCID	50.43	103
10	Pre-Clinical Intravenous Serum Pharmacokinetics of Albumin B… (10.3390/antib4030141)	ORCID	50.00	99
11	Antibody Glycosylation and Inflammation (10.3390/antib2030392)	ORCID	49.78	97
12	Antibody Fragments and Their Purification by Protein L Affin… (10.3390/antib4030259)	ORCID	49.21	92
13	From Anti-SARS-CoV-2 Immune Responses to COVID-19 via Molecu… (10.3390/antib9030033)	ORCID	49.09	91
14	Antibody Drug Conjugates as Cancer Therapeutics (10.3390/antib2010113)	ORCID	48.36	85
15	Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy (10.3390/antib4010048)	ORCID	46.73	73
16	Immunogenicity of Innovative and Biosimilar Monoclonal Antib… (10.3390/antib8010021)	ORCID	46.13	69
17	Cell-Free Synthesis Meets Antibody Production: A Review (10.3390/antib4010012)	ORCID	45.15	63
18	Clinical Pharmacology of Antibody-Drug Conjugates (10.3390/antib10020020)	ORCID	44.81	61
19	Shark Variable New Antigen Receptor (VNAR) Single Domain Ant… (10.3390/antib2010066)	ORCID	44.63	60
20	Proteolysis-Targeting Chimera (PROTAC) Delivery into the Bra… (10.3390/antib12030043)	ORCID	44.09	57
21	Pharmacokinetic and Pharmacodynamic Considerations for the U… (10.3390/antib7010005)	ORCID	43.70	55
22	Beyond the Lactate Paradox: How Lactate and Acidity Impact T… (10.3390/antib10030025)	ORCID	43.51	54
23	Single-Domain Antibodies as Therapeutic and Imaging Agents f… (10.3390/antib8020027)	ORCID	43.51	54
24	Antibody-Based Immunotoxins for the Treatment of Cancer (10.3390/antib1010039)	ORCID	43.31	53
25	Enzyme-Based Labeling Strategies for Antibody–Drug Conjugate… (10.3390/antib7010004)	ORCID	43.31	53
26	Molecular Engineering of Therapeutic Cytokines (10.3390/antib2030426)	ORCID	42.25	48
27	Engineering IgG-Like Bispecific Antibodies—An Overview (10.3390/antib7030028)	ORCID	42.25	48
28	Therapeutic Monoclonal Antibodies Targeting Immune Checkpoin… (10.3390/antib8040051)	ORCID	41.57	45
29	Recent Advances in the Molecular Design and Applications of… (10.3390/antib10020013)	ORCID	40.32	40
30	Targeting of Tumor Necrosis Factor Alpha Receptors as a Ther… (10.3390/antib4040369)	ORCID	40.05	39
31	ADME Considerations and Bioanalytical Strategies for Pharmac… (10.3390/antib7040041)	ORCID	40.05	39
32	Human Natural Antibodies to Mammalian Carbohydrate Antigens… (10.3390/antib9020025)	ORCID	40.05	39
33	Current and Potential Uses of Immunocytokines as Cancer Immu… (10.3390/antib1020149)	ORCID	39.78	38
34	Functional, Biophysical, and Structural Characterization of… (10.3390/antib6030012)	ORCID	39.78	38
35	Antibody-Directed Phototherapy (ADP) (10.3390/antib2020270)	ORCID	39.49	37
36	VNARs: An Ancient and Unique Repertoire of Molecules That De… (10.3390/antib4030240)	ORCID	39.49	37
37	A Rabbit Monoclonal Antibody against the Antiviral and Cance… (10.3390/antib8030047)	ORCID	38.91	35
38	Ricin and Ricin-Containing Immunotoxins: Insights into Intra… (10.3390/antib2020236)	ORCID	38.29	33
39	In Silico Methods in Antibody Design (10.3390/antib7030022)	ORCID	37.96	32
40	Delivery of Drugs into Cancer Cells Using Antibody–Drug Conj… (10.3390/antib11040078)	ORCID	37.63	31
41	A Polar Sulfamide Spacer Significantly Enhances the Manufact… (10.3390/antib7010012)	ORCID	37.63	31
42	IMGT® and 30 Years of Immunoinformatics Insight in Antibody… (10.3390/antib8020029)	ORCID	37.63	31
43	Ion Channel Targeting with Antibodies and Antibody Fragments… (10.3390/antib8020033)	ORCID	37.28	30
44	Cancer Immunotherapy by Retargeting of Immune Effector Cells… (10.3390/antib1020172)	ORCID	36.93	29
45	Process Analytical Approach towards Quality Controlled Proce… (10.3390/antib6040024)	ORCID	36.93	29
46	The Biotechnological Applications of Recombinant Single-Doma… (10.3390/antib3020182)	ORCID	36.56	28
47	Pharmacologic Considerations in the Disposition of Antibodie… (10.3390/antib8010003)	ORCID	36.56	28
48	Taking up Cancer Immunotherapy Challenges: Bispecific Antibo… (10.3390/antib5010001)	ORCID	36.18	27
49	Evaluation of Continuous Membrane Chromatography Concepts wi… (10.3390/antib7010013)	ORCID	36.18	27
50	Immunoglobulin for Treating Bacterial Infections: One More M… (10.3390/antib8040052)	ORCID	36.18	27